Within days of the US Food and Drug Administration’s emergency use authorization for Pfizer’s Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use), Bangladesh’s Beximco Pharmaceuticals announced that it had rolled out the first cut-price generic of the oral pill for the treatment of mild-to-moderate COVID-19.
Rabbur Reza, Beximco Pharmaceuticals' chief operating officer, told Generics Bulletin sister publication Scrip that the company had developed the product...




